Industry Briefs: December 17, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: December 17, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

The Court of Appeals for the Federal Circuit has upheld the decision of the District Court, District of Delaware, finding that the US substance patent protecting AstraZeneca’s Crestor (rosuvastatin calcium) (RE37,314 – the ‘314 patent) is valid and enforceable. Read More

Avid Bioservices has completed its biofacility upgrades in response to increased demand for its contract manufacturing, the company says. Read More

Catalent Pharma Solutions and UMN Pharma have formed a collaboration for biosimilar development and production in Japan. Read More

Chemsultants International has added a Class 10,000/Class 1000 cleanroom to its product- and process-development operations. Read More

Cobalt Light Systems has expanded its capacity and relocated into a larger facility in Abingdon, Oxfordshire, United Kingdom. Read More

Elite Pharmaceuticals has formed an agreement for the next year with the company’s sole supplier of the API for Elite’s phentermine product lines that include phentermine HCl tablets (37.5 mg) and phentermine HCl capsules (15 and 30 mg). Read More

Evotec has a license agreement with Janssen Pharmaceuticals regarding its NR2B subtype selective NMDA-antagonist portfolio for development against diseases in the field of depression. Read More

Phenex Pharmaceuticals and Janssen Biotech have formed a research collaboration and license agreement for autoimmune and chronic inflammatory disorders. Read More

Sartorius Stedim Biotech has formed a sales partnership with Umetrics to expand its process analytical technology software portfolio for the optimization of biopharmaceutical development and manufacturing processes. Read More

People News

Amgen has named CEO Robert A. Bradway chairman of its board of directors. Read More

Impax Laboratories has appointed Bryan M. Reasons as senior vice-president and chief financial officer. Read More

Sanofi has announced that Hanspeter Spek, president, global operations, will retire from his current role in mid-2013. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
42%
Facility/environment problems
0%
Process development problems
8%
Production equipment downtime
8%
Raw material supply problems
25%
Regulatory restrictions
0%
Business decisions to limit production
17%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced

Click here